Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
There is no financial score for this company; the Pharmaceuticals industry's average is 7.77.
Key Metrics
The company’s current valuation score is 7.07, which is lower than the Pharmaceuticals industry's average of 7.19. Its current P/E ratio is -0.96, which is -100.00% below the recent high of 0.00 and -5.26% above the recent low of -1.01.
The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for PolyPid Ltd is 13.00, with a high of 14.00 and a low of 10.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The company’s current price momentum score is 5.36, which is lower than the Pharmaceuticals industry's average of 7.05. Sideways: Currently, the stock price is trading between the resistance level at 3.88 and the support level at 3.20, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.59. The latest institutional shareholding proportion is 41.20%, representing a quarter-over-quarter decrease of 44.75%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.
There is no risk assessment score for the company; the Pharmaceuticals industry's average is 5.11. The company's beta value is 1.52. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
